Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
2.
Eur Respir J ; 56(5)2020 Nov.
Article in English | MEDLINE | ID: mdl-32907891

ABSTRACT

INTRODUCTION: Pneumothorax and pneumomediastinum have both been noted to complicate cases of coronavirus disease 2019 (COVID-19) requiring hospital admission. We report the largest case series yet described of patients with both these pathologies (including nonventilated patients). METHODS: Cases were collected retrospectively from UK hospitals with inclusion criteria limited to a diagnosis of COVID-19 and the presence of either pneumothorax or pneumomediastinum. Patients included in the study presented between March and June 2020. Details obtained from the medical record included demographics, radiology, laboratory investigations, clinical management and survival. RESULTS: 71 patients from 16 centres were included in the study, of whom 60 had pneumothoraces (six with pneumomediastinum in addition) and 11 had pneumomediastinum alone. Two of these patients had two distinct episodes of pneumothorax, occurring bilaterally in sequential fashion, bringing the total number of pneumothoraces included to 62. Clinical scenarios included patients who had presented to hospital with pneumothorax, patients who had developed pneumothorax or pneumomediastinum during their inpatient admission with COVID-19 and patients who developed their complication while intubated and ventilated, either with or without concurrent extracorporeal membrane oxygenation. Survival at 28 days was not significantly different following pneumothorax (63.1±6.5%) or isolated pneumomediastinum (53.0±18.7%; p=0.854). The incidence of pneumothorax was higher in males. 28-day survival was not different between the sexes (males 62.5±7.7% versus females 68.4±10.7%; p=0.619). Patients aged ≥70 years had a significantly lower 28-day survival than younger individuals (≥70 years 41.7±13.5% survival versus <70 years 70.9±6.8% survival; p=0.018 log-rank). CONCLUSION: These cases suggest that pneumothorax is a complication of COVID-19. Pneumothorax does not seem to be an independent marker of poor prognosis and we encourage continuation of active treatment where clinically possible.


Subject(s)
COVID-19/complications , Mediastinal Emphysema/epidemiology , Mediastinal Emphysema/virology , Pneumothorax/epidemiology , Pneumothorax/virology , SARS-CoV-2 , Adult , Age Factors , Aged , Aged, 80 and over , COVID-19/mortality , COVID-19/therapy , Extracorporeal Membrane Oxygenation , Female , Hospitalization , Humans , Incidence , Male , Mediastinal Emphysema/therapy , Middle Aged , Pneumothorax/therapy , Prognosis , Respiration, Artificial , Retrospective Studies , Sex Factors , Survival Rate , United Kingdom , Young Adult
3.
BMJ Case Rep ; 13(8)2020 Aug 11.
Article in English | MEDLINE | ID: mdl-32784238

ABSTRACT

The COVID-19 pandemic has had a significant impact on the structure and operation of healthcare services worldwide. We highlight a case of a 64-year-old man who presented to the emergency department with acute dyspnoea on a background of a 2-week history of fever, dry cough and shortness of breath. On initial assessment the patient was hypoxic (arterial oxygen saturation (SaO2) of 86% on room air), requiring 10 L/min of oxygen to maintain 98% SaO2 Examination demonstrated left-sided tracheal deviation and absent breath sounds in the right lung field on auscultation. A chest radiograph revealed a large right-sided tension pneumothorax which was treated with needle thoracocentesis and a definitive chest drain. A CT pulmonary angiogram demonstrated segmental left lower lobe acute pulmonary emboli, significant generalised COVID-19 parenchymal features, surgical emphysema and an iatrogenic pneumatocoele. This case emphasises the importance of considering coexisting alternative diagnoses in patients who present with suspected COVID-19.


Subject(s)
Betacoronavirus/isolation & purification , Coronavirus Infections/complications , Pneumonia, Viral/complications , Pneumothorax/complications , Pulmonary Embolism/complications , Anti-Bacterial Agents/therapeutic use , Anticoagulants/therapeutic use , COVID-19 , Coronavirus Infections/diagnosis , Coronavirus Infections/therapy , Drainage , Humans , Lung/diagnostic imaging , Male , Middle Aged , Oxygen Inhalation Therapy , Pandemics , Pneumonia, Viral/diagnosis , Pneumonia, Viral/therapy , Pneumothorax/diagnostic imaging , Pneumothorax/therapy , Pulmonary Embolism/diagnostic imaging , Pulmonary Embolism/drug therapy , Radiography, Thoracic , SARS-CoV-2 , Tinzaparin/therapeutic use , Tomography, X-Ray Computed
SELECTION OF CITATIONS
SEARCH DETAIL
...